A Study of Nonoxynol-9 (N-9) and HIV Infection

Completed · Phase 3

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if nonoxynol-9 (N-9) gel used in the vagina can prevent the spread of HIV. Most of the people with HIV in the world today live in southern Africa. Because this population is not likely to use condoms, an HIV-prevention method that women can control is needed. N-9 used in the vagina may help prevent the spread of HIV and other sexually transmitted diseases.

Key facts

Study ID

NCT00000926

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

4400

Expected to finish

2001-02-01

Last updated by the study team

2021-10-29

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Volunteers may be eligible if they:
• Are HIV-negative.
• Are sexually active and expect to have vaginal intercourse at least twice a week during the study.
• Are willing to keep a diary of their sexual behavior and N-9 use.
• Are willing to have regular clinic visits including pelvic exams.
• Are at least 18 years old.
• Are female.

You may not qualify if…

• Volunteers will not be eligible if they:
• Have had a child or an abortion in the past 42 days.
• Are allergic to latex or N-9.
• Have genital sores.
• Have syphilis, chlamydia, gonorrhea, or trichomoniasis.
• Are enrolled in another study for a product like N-9.
• Expect to use another vaginal product other than N-9 during the study.
• Are pregnant.

Where it is running

• Julia Welch — Research Triangle Park, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.